Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

Clinical trial NCT07730125 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07730125
Sponsor: CoRegen, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HR-positive, HER2-negative Breast Cancer TNBC - Triple-Negative Breast Cancer Prostate Cancer

Start date: 2026-11-01
Primary completion: 2029-06-01
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.